COST-EFFECTIVENESS OF QUETIAPINE EXTENDED RELEASE VERSUS OTHER ATYPICAL ANTIPSYCHOTICS IN ACUTE BIPOLAR DEPRESSION

被引：0
|
作者：
Meier, G. [1 ]
Edwards, S. J. [1 ]
von Maltzahn, R. [1 ]
机构：
[1] AstraZeneca UK Ltd, Luton, Beds, England
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74768-9
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A360 / A360
页数：1
相关论文
共 50 条
  • [21] MOOD STABILIZERS AND ATYPICAL ANTIPSYCHOTICS IN MAINTENANCE THERAPY FOR BIPOLAR DISORDER: A COST-EFFECTIVENESS ANALYSIS
    Zimmermann, I. R.
    Kiyomoto, H. D.
    Alexandre, R. F.
    Nobre, M. R. C.
    Diaz, M. D. M.
    VALUE IN HEALTH, 2013, 16 (07) : A548 - A548
  • [22] Effectiveness of lithium versus quetiapine extended release monotherapy in patients with bipolar spectrum disorder
    Gao, K.
    Goto, T.
    Brownrigg, B.
    Conroy, C.
    Chan, P.
    Serrano, M. B.
    Ganocy, S.
    Calabrese, J.
    BIPOLAR DISORDERS, 2016, 18 : 98 - 98
  • [23] Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression (vol 121, pg 106, 2009)
    Suppes, Trisha
    Datto, Catherine
    Minkwitz, Margaret
    Nordenhem, Arvid
    Walker, Chris
    Darko, Denis
    JOURNAL OF AFFECTIVE DISORDERS, 2014, 168 : 484 - 484
  • [24] Effectiveness of the Extended Release Formulation of Quetiapine as Monotherapy for the Treatment of Acute Bipolar Depression (vol 121, pg 106, 2010)
    Suppes, Trisha
    Datto, Catherine
    Minkwitz, Margaret
    Nordenhem, Arvid
    Walker, Chris
    Darko, Denis
    JOURNAL OF AFFECTIVE DISORDERS, 2014, 168 : 485 - 493
  • [25] Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK
    Davies, Andrew
    Vardeva, Kawitha
    Loze, Jean-Yves
    L'Italien, Gilbert J.
    Sennfalt, Karin
    van Baardewijk, Marc
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (11) : 3275 - 3285
  • [26] Cost-effectiveness of atypical antipsychotics in the CATIE schizophrenia trial
    Rosenheck, RA
    NEUROPSYCHOPHARMACOLOGY, 2005, 30 : S32 - S32
  • [27] Methods and applications of cost-effectiveness modeling for atypical antipsychotics
    Revicki, D. A.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S39 - S39
  • [28] Discontinuation Rate of Lurasidone and Quetiapine Extended Release in Bipolar Depression
    Kishi, Taro
    Sakuma, Kenji
    Hamanaka, Shun
    Nishii, Yasufumi
    Iwata, Nakao
    PHARMACOPSYCHIATRY, 2024, 57 (05) : 245 - 248
  • [29] THE COST-EFFECTIVENESS OF QUETIAPINE EXTENDED-RELEASE VERSUS OLANZAPINE FOLLOWING GENERIC RISPERIDONE IN PATIENTS WITH FIRST EPISODE SCHIZOPHRENIA
    Meier, G.
    VALUE IN HEALTH, 2008, 11 (06) : A583 - A583
  • [30] Cost-effectiveness of Paliperidone Palmitate Versus other Antipsychotics for the Treatment of Schizophrenia in France
    Doutriaux, A.
    Druais, S.
    Cognet, M.
    Lancon, C.
    Samalin, L.
    Levy, P.
    Godet, A.
    Guillon, P.
    JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2015, 18 : S11 - S12
12345